Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test
In another blow to Prothena’s neurodegenerative disease portfolio, anti-amyloid candidate PRX012 has run into the same problem that larger peers Biogen and Eli Lilly have battled: high rates of swelling in the brain.
Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test Read More »
